Achilles Therapeutics plc Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 11/14/2024 | 11.09 M | $11.31 M | 0.00% | 27.47% |
| BML CAPITAL MANAGEMENT, LLC | 11/05/2024 | 4.10 M | $4.18 M | 555.82% | 10.16% |
| FCPM III SERVICES B.V. | 11/14/2024 | 2.39 M | $2.44 M | 0.00% | 5.92% |
| REDMILE GROUP, LLC | 11/14/2024 | 1.61 M | $1.64 M | 0.00% | 3.98% |
| VESTAL POINT CAPITAL, LP | 11/14/2024 | 1.50 M | $1.53 M | 0.00% | 3.72% |
| IKARIAN CAPITAL, LLC | 11/14/2024 | 1.44 M | $1.47 M | 0.00% | 3.58% |
| SIREN, L.L.C. | 11/13/2024 | 755,375 | $770.48 M | 100.00% | 1.87% |
| RENAISSANCE TECHNOLOGIES LLC | 11/13/2024 | 638,133 | $650,896 | -6.53% | 1.58% |
| BOOTHBAY FUND MANAGEMENT, LLC | 11/14/2024 | 420,481 | $428,891 | 0.00% | 1.04% |
| ACADIAN ASSET MANAGEMENT LLC | 11/12/2024 | 250,825 | $255,000 | 0.00% | 0.62% |
| TWO SIGMA ADVISERS, LP | 11/14/2024 | 22,400 | $22,848 | -4.68% | 0.06% |
| GEODE CAPITAL MANAGEMENT, LLC | 11/12/2024 | 21,590 | $22,021 | 0.00% | 0.05% |
| TWO SIGMA INVESTMENTS, LP | 11/14/2024 | 21,249 | $21,674 | -1.07% | 0.05% |
| CORSAIR CAPITAL MANAGEMENT, L.P. | 11/13/2024 | 20,000 | $20,400 | 100.00% | 0.05% |
| MORGAN STANLEY | 11/14/2024 | 16,431 | $16,760 | 83.98% | 0.04% |
| BAADER BANK AKTIENGESELLSCHAFT | 10/29/2024 | 14,184 | $10,365 | 14.67% | 0.04% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 11/14/2024 | 12,434 | $12,683 | 100.00% | 0.03% |
| BRAVE ASSET MANAGEMENT INC | 10/10/2024 | 10,000 | $10,200 | 0.00% | 0.02% |
| RHUMBLINE ADVISERS | 11/12/2024 | 4,480 | $4,569 | 0.00% | 0.01% |
| ARCADIA INVESTMENT MANAGEMENT CORP/MI | 10/29/2024 | 3,000 | $3,060 | 100.00% | 0.01% |
| JPMORGAN CHASE & CO | 11/08/2024 | 137 | $140 | 0.00% | 0.00% |
| BANK OF AMERICA CORP /DE/ | 11/14/2024 | 15 | $15 | 100.00% | 0.00% |
| ARTAL GROUP S.A. | 11/13/2024 | 0 | $0 | -100.00% | 0.00% |
| BAKER BROS. ADVISORS LP | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| CITADEL ADVISORS LLC | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| HRT FINANCIAL LP | 11/12/2024 | 0 | $0 | -100.00% | 0.00% |
| VIRTU FINANCIAL LLC | 11/20/2024 | 0 | $0 | -100.00% | 0.00% |
| UBS GROUP AG | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| QUBE RESEARCH & TECHNOLOGIES LTD | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| GLOBAL RETIREMENT PARTNERS, LLC | 10/16/2024 | 0 | $0 | -100.00% | 0.00% |
| XTX TOPCO LTD | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
Achilles Therapeutics plcinstitutional Ownership - FAQ's
During the previous two years, 32 institutional investors and hedge funds held shares of Achilles Therapeutics plc. The most heavily invested institutionals were:
Syncona Portfolio Ltd: 11.09 M
BML Capital Management, LLC: 4.1 M
FCPM III SERVICES B.V.: 2.39 M
Redmile Group, LLC: 1.61 M
Vestal Point Capital, LP: 1.5 M
Ikarian Capital, LLC: 1.44 M
60.31% of Achilles Therapeutics plc stock is owned by institutional investors.
Institutional investors have bought a total of 24.34 M shares in the last 24 months. This purchase volume represents approximately $23.85 M in transactions.